Добірка наукової літератури з теми "HIV-1 proteasi"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "HIV-1 proteasi".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "HIV-1 proteasi"
Pan, Bowen, Sumei Li, Junwei Xiao, Xin Yang, Shouxia Xie, Ying Zhou, Jian Yang, and Ying Wei. "Dual Inhibition of HIV-1 and Cathepsin L Proteases by Sarcandra glabra." Molecules 27, no. 17 (August 29, 2022): 5552. http://dx.doi.org/10.3390/molecules27175552.
Повний текст джерелаPark, Jung-Ho, Yoshihiro Yamaguchi, and Masayori Inouye. "Intramolecular Regulation of the Sequence-Specific mRNA Interferase Activity of MazF Fused to a MazE Fragment with a Linker Cleavable by Specific Proteases." Applied and Environmental Microbiology 78, no. 11 (March 23, 2012): 3794–99. http://dx.doi.org/10.1128/aem.00364-12.
Повний текст джерелаCapel, Elena, Glòria Martrus, Mariona Parera, Bonaventura Clotet, and Miguel Angel Martínez. "Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness." Journal of General Virology 93, no. 12 (December 1, 2012): 2625–34. http://dx.doi.org/10.1099/vir.0.045492-0.
Повний текст джерелаMartínez, Miguel-Angel, Marta Cabana, Mariona Parera, Arantxa Gutierrez, José A. Esté, and Bonaventura Clotet. "A Bacteriophage Lambda-Based Genetic Screen for Characterization of the Activity and Phenotype of the Human Immunodeficiency Virus Type 1 Protease." Antimicrobial Agents and Chemotherapy 44, no. 5 (May 1, 2000): 1132–39. http://dx.doi.org/10.1128/aac.44.5.1132-1139.2000.
Повний текст джерелаMcPHEE, Fiona, Patricia S. CALDERA, Guy W. BEMIS, Antony F. McDONAGH, Irwin D. KUNTZ, and Charles S. CRAIK. "Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro." Biochemical Journal 320, no. 2 (December 1, 1996): 681–86. http://dx.doi.org/10.1042/bj3200681.
Повний текст джерелаRaugi, Dana N., Robert A. Smith, and Geoffrey S. Gottlieb. "Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors." Journal of Virology 90, no. 2 (November 11, 2015): 1062–69. http://dx.doi.org/10.1128/jvi.01772-15.
Повний текст джерелаÁlvarez, Enrique, Luis Menéndez-Arias, and Luis Carrasco. "The Eukaryotic Translation Initiation Factor 4GI Is Cleaved by Different Retroviral Proteases." Journal of Virology 77, no. 23 (December 1, 2003): 12392–400. http://dx.doi.org/10.1128/jvi.77.23.12392-12400.2003.
Повний текст джерелаÁlvarez, Enrique, Alfredo Castelló, Luis Menéndez-Arias, and Luis Carrasco. "HIV protease cleaves poly(A)-binding protein." Biochemical Journal 396, no. 2 (May 15, 2006): 219–26. http://dx.doi.org/10.1042/bj20060108.
Повний текст джерелаDAVIS, David A., Fonda M. NEWCOMB, Jackob MOSKOVITZ, Paul T. WINGFIELD, Stephen J. STAHL, Joshua KAUFMAN, Henry M. FALES, Rodney L. LEVINE, and Robert YARCHOAN. "HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase." Biochemical Journal 346, no. 2 (February 22, 2000): 305–11. http://dx.doi.org/10.1042/bj3460305.
Повний текст джерелаSohraby, Farzin, and Hassan Aryapour. "Comparative analysis of the unbinding pathways of antiviral drug Indinavir from HIV and HTLV1 proteases by supervised molecular dynamics simulation." PLOS ONE 16, no. 9 (September 27, 2021): e0257916. http://dx.doi.org/10.1371/journal.pone.0257916.
Повний текст джерелаДисертації з теми "HIV-1 proteasi"
PAROLIN, DEBORA. "MESSA A PUNTO DI TEST ALTERNATIVI PER LO SCREENING DI POTENZIALI INIBITORI DELLA PROTEASI DI HIV-1." Doctoral thesis, Università degli Studi di Milano, 2014. http://hdl.handle.net/2434/231147.
Повний текст джерелаDemitri, Nicola. "Studi strutturali di sistemi proteici e supramolecolari - studi sulla fosfodiesterasi umana,sulla proteasi da HIV-1 e su nuove classi di resorcinareni." Doctoral thesis, Università degli studi di Trieste, 2010. http://hdl.handle.net/10077/3520.
Повний текст джерелаDurante i tre anni della Scuola di Dottorato in Scienze e Tecnologie Chimiche e Farmaceutiche, il Dott. Demitri Nicola si è dedicato ad un progetto di ricerca riguardante lo studio strutturale mediante diffrazione di raggi-X di diversi sistemi proteici e complessi supramolecolari. I progetti di studio sviluppati in questi tre anni di ricerca hanno riguardato: 1. Studi strutturali di complessi della proteasi da HIV-1 con nuovi inibitori. Questo enzima è un target d’elezione nel structure based drug design e nella terapia antiretrovirale attualmente adottata per il trattamento dell’AIDS. La messa a punto dei protocolli di espressione della proteina ricombinante in sistema E. coli e delle tecniche di purificazione cromatografiche ha garantito livelli di concentrazione e purezza della proteina, adeguati a fornire cristalli di dimensioni adatte agli esperimenti di diffrazione di raggi-X per lo studio strutturale mediante tecniche biocristallografiche dell’enzima in complesso con tre diversi inibitori: il farmaco commerciale, Saquinavir (SQV), e due nuove molecole sintetiche (FT99 ed EPX). Dati strutturali ad alta risoluzione di una nuova forma cristallina del complesso PR/SQV sono stati ottenuti ed hanno mostrato la presenza di disordine dell’inibitore nel sito catalitico, permettendo di discutere del fenomeno, anche in relazione ai dati strutturali già presenti in letteratura. È stata inoltre riscontrata la carbamoilazione della prolina N-terminale della proteina causata dall’utilizzo di urea come agente caotropico e ciò rappresenta la prima evidenza strutturale di tale fenomeno. Sono stati anche studiati due nuovi inibitori sviluppati nel laboratorio della Prof. Funicello (Università Degli Studi della Basilicata) e nel laboratorio del Prof. Benedetti (Università Degli Studi di Trieste): FT99 è un inibitore reversibile basato su uno scaffold sulfonammidico, mentre EPX è un isostere Phe-Phe, basato su una funzionalità epossidica e quindi disegnato per legare covalentemente la proteina ed agire come inibitore irreversibile. Cocristallizzando la proteasi con FT99 si è riscontrata l’assenza dell’inibitore nel sito catalitico (nei cristalli analizzati) e ciò può essere correlato alla relativa bassa affinità di questo inibitore per l’enzima. I dati strutturali sono stati comunque utili per indagare sulla struttura della apoproteina e per suggerire delle modifiche che portino a migliorie delle proprietà inibitorie di questo lead compound. Le mappe di densità elettronica, ottenute dai dati diffrazione del complesso PR/EPX, cristallizzato a pH 6, hanno mostrato il sito catalitico occupato in modo ordinato dall’inibitore che possedeva l’anello epossidico intatto. Questo risultato è particolarmente interessante vista l’elevata reattività che il gruppo funzionale epossidico normalmente manifesta. Per verificare questa reattività si è provato ad innescare la reazione di apertura dell’anello direttamente nel cristallo del complesso PR/EPX aumentando a 9 il pH mediante diffusione di ammoniaca. L’alterazione del pH non ha mostrato un danneggiamento dei cristalli ed il modello strutturale ottenuto dai dati di diffrazione raccolti ha mostrato che l’inibitore reagisce aprendo l’anello epossidico in modo stereospecifico per addizione di ammoniaca. 2. Espressione e purificazione della fosfodiesterasi umana PDE4B2, volta alla caratterizzazione strutturale di complessi di questo enzima con nuovi inibitori. Quest’attività di ricerca è stata condotta in collaborazione con la Chiesi Farmaceutici e con il laboratorio diretto dal Dott. Gianluca Tell dell’Università degli Studi di Udine. Le PDE hanno un ruolo fondamentale nelle patologie infiammatorie (come asma, psoriasi e dermatite allergica), e lo sviluppo di farmaci specifici in grado di regolare selettivamente l’attività di questi enzimi è particolarmente rilevante per lo sviluppo di nuovi farmaci antinfiammatori. All’inizio è stata svolta una ricerca bibliografica per conoscere le strutture e le sequenze primarie delle proteine PDE4 già cristallizzate, presenti in letteratura. Ciò ha permesso di evidenziare la sequenza del dominio catalitico della variante PDE4B2 adatta alla cristallizzazione. Scelta la sequenza da esprimere, nel laboratorio del Dott. Gianluca Tell è stato prodotto il plasmide contenente il gene della proteina scelta. Inizialmente si è deciso di provare ad usare il vettore di espressione pGEX-2T, col quale ci si è concentrati sulla purificazione della proteina di fusione GST-PDE4B2. Avendo riscontrato diverse problematiche nella purificazione di questo costrutto, si è deciso di passare all’espressione e purificazione del dominio catalitico della proteina PDE4B2 fusa con l’(His)6Tag. Purtroppo, dopo aver messo a punto un protocollo per la purificazione in condizioni denaturanti, non si è riusciti ad ottenere cristalli di proteina adatti agli studi tramite diffrazione di raggi X. Il progetto è rimasto perciò aperto ad ulteriori sviluppi, mirati al completamento della caratterizzazione strutturale, cercando nuovi approcci di purificazione della proteina in condizioni denaturanti e nuovi protocolli di purificazione che non prevedano l’uso di agenti caotropici. 3. Determinazione strutturale di sistemi supramolecolari di cavitandi chirali e non, funzionalizzati al bordo superiore con gruppi fosfonici e tiofosfonici. Quest’attività di ricerca è stata condotta in collaborazione con il gruppo del Prof. Dalcanale del Dipartimento di Chimica Organica e Industriale dell’Università di Parma. I sistemi supramolecolari in linea generale sono caratterizzati da specifiche interazioni host/guest. Il fatto che tali legami siano non-covalenti rappresenta uno dei punti di forza per questo tipo di recettori, in quanto alla base del riconoscimento molecolare c’è la possibilità di poter correggere il complesso host/guest attraverso la facile rottura e formazione di interazioni deboli. Questi sistemi sono utilizzabili come recettori, sensori di massa e dynamer, nuovi materiale interessanti dal punto di vista tecnologico, costituito da componenti modulari, di dimensioni nanometriche, capaci di rispondere a stimoli esterni. Durante questo dottorato sono stati analizzati due sistemi molto diversi. Il primo di questi è una specie capace di auto assemblare per dare spontaneamente origine a polimeri supramolecolari. La caratterizzazione di questo monomero resorcinarenico allo stato solido conferma la capacità che ha questo in soluzione di dare polimeri lineari (peculiarità confermata da misure NMR e SLS). La molecola ha mostrato di poter autoassemblare in catene polimeriche le quali si affiancano in modo ordinato allo stato solido. L’altra molecola analizzata (2PO1PSME) è un cavitando chirale utilizzabile come recettore o sensore di massa, per alcoli chirali. Lo studio di questa specie è passato attraverso una fase di messa a punto di un protocollo di purificazione del composto racemo, tramite cromatografia di affinità ottenuta per funzionalizzazione di una resina con l’amminoacido naturale treonina. La successiva caratterizzazione mediante diffrazione a raggi-X del cavitando chirale, seppur ottenuta in forma racemica, ha permesso di ottenere le caratteristiche strutturali di questo promettente recettore chirale.
XXII Ciclo
1981
Chong, Sannie Siaw Foong. "Anisotropic potential HIV-1 protease inhibitors." Thesis, University of Hull, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.327289.
Повний текст джерелаSchaal, Wesley. "Computational Studies of HIV-1 Protease Inhibitors." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2002. http://publications.uu.se/theses/91-554-5213-2/.
Повний текст джерелаHarburn, James J. "Novel steroidal inhibitors of HIV-1 protease." Thesis, Loughborough University, 1998. https://dspace.lboro.ac.uk/2134/14701.
Повний текст джерелаMartins, Nádia Helena. "Ensaios enzimáticos de proteases de HIV-1 de subtipos brasileiros." Universidade de São Paulo, 2007. http://www.teses.usp.br/teses/disponiveis/76/76132/tde-27042008-122417/.
Повний текст джерелаDespite years of intense research around the world, HIV continues to represent considerable therapeutical challenge. In order to gain more insights into resistance of polymorphic mutations of existing HIV subtypes toward commercially available pharmaceutics, we studied inhibition of subtypes B and F HIV proteases (PRs) [native and two mutant enzymes clinically identified in Brazilian patients] by six commercial inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir). Our results show that all these inhibitors have significantly higher Ki values for the subtype F HIV PR (Fwt) and both mutant enzymes than that for the B subtype HIV PR (Bwt). Furthermore, the biochemical fitnesses of these proteases, or their vitalities, are also considerably higher than that of Bwt. The accumulation of commonly detected resistant mutations in HIV PRs with natural polymorphisms turns Fwt sufficiently catalytically active to guarantee the virus viability and confers it a large degree of cross resistance against all studied inhibitors.
Alterman, Mathias. "Design and synthesis of HIV-1 protease inhibitors." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.- bibl. [distributör], 2001. http://publications.uu.se/theses/91-554-4906-9/.
Повний текст джерелаPersson, Magnus. "Structural Studies of Bacteriophage PRR1 and HIV-1 protease." Doctoral thesis, Uppsala universitet, Strukturell molekylärbiologi, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-135159.
Повний текст джерелаFelaktigt tryckt som Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 724
Windsor, Ian William. "HIV-1 protease as a target for antiretroviral therapy." Thesis, Massachusetts Institute of Technology, 2019. https://hdl.handle.net/1721.1/122533.
Повний текст джерелаCataloged from PDF version of thesis.
Includes bibliographical references (pages 395-424).
Human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). HIV employs three enzymes in its lifecycle, including a protease that enables maturation of polyprotein precursors. Despite decades of progress studying the lifecycle of HIV and elaboration of therapeutics targeting nearly every aspect of the viral life cycle, a cure remains elusive. Breakthroughs in HIV research have occurred alongside foundational advances of molecular biology, biotechnology, and medicinal chemistry, highlighting the importance revisiting old questions with new approaches. The goal of this thesis is to advance our biochemical knowledge of HIV-I protease and develop novel therapeutics targeting this key viral enzyme. In Chapter 1, I introduce HIV and the role that HIV-1 protease plays in life cycle and current treatment strategies.
In Chapter 2, I describe an assay that enables the determination of sub-picomolar inhibition constants for competitive inhibitors of HIV-1 protease. This advance was made possible by a peptide substrate selected by phage display. I report in Chapter 3 the enhanced hydrogen bonding in the recognition of this peptide by HIV-1 protease as revealed by X-ray crystallography. The mechanism of aspartic proteases, including HIV-1 protease, has been the subject of numerous enzymology studies spanning over half a century. In Chapter 4, I reveal unappreciated non-covalent interactions within substrates of aspartic proteases that assist in catalysis. In addition to biochemical studies, this thesis includes chapters that account the development of novel antivirals. In Chapter 5, I describe the rational drug design of a boronic acid analog of the clinical inhibitor darunavir with improved potency.
A limitation of boronic acids is metabolic instability; in Chapter 6, I reveal an intramolecular protecting group that can confer oxidative stability to boronic acids. Finally, in Chapter 7, I describe an engineering approach to inactivate human RNase 1. The inactivation relies on installing a substrate for HIV- I protease, the cleavage of which unmasks cytotoxic activity. Together these chapters describe new ways forward and novel therapeutics targeting HIV-1 protease. My thesis also includes an Appendix, which describes the elaboration of boronic acid-based covalent pharmacological chaperones of human transthyretin.
by Ian William Windsor.
Ph. D.
Ph.D. Massachusetts Institute of Technology, Department of Chemistry
Muller, Natalie Guida. "Identificação de epitopos da protease de HIV-1 alvos de respostas de células T CD4+ em pacientes infectados pelo HIV-1." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5146/tde-05032010-170301/.
Повний текст джерелаIntroduction: A significant proportion of protease inhibitor (PI)-treated HIV-1 infected (HIV-1+) patients develop resistance mutations. Recent studies have shown that CD8+ T cells from HIV-1 patients can recognize antiretroviral drug-induced mutant Pol epitopes. No HIV-1 protease CD4 epitopes are described in the Los Alamos database. Aims: Given that the protease of HIV-1 is a target of antiretroviral therapy and this pressure may lead to the selection of mutations, we investigated whether PI-induced mutations affect the recognition of HIV-1 protease epitopes by CD4 + T cells in PI-treated patients. We investigated the recognition of three protease regions predicted to harbor CD4+ T cell epitopes as well as PI-induced mutations by CD4+ T cells of PI-treated HIV-1+ patients. Methods: Forty PI-treated HIV-1+ patients were included (30 undergoing Lopinavir/ritonavir, 9 undergoing Atazanavir/ritonavir and 1 undergoing exclusively Atazanavir treatment). For each patients, the endogenous HIV-1 protease sequence, viral genotype and HLA class II typing were determined. We used the TEPITOPE algorithm to select promiscuous, multiple HLA-DR-binding peptides encoding 3 regions of HIV-1 HXB2 strain protease (HXB2 4-23, 45-64, and 76-95) and 32 additional peptides contained in the same regions, but encompassing the most frequent PI-induced mutations in Brazil. The 35 peptides were thus synthesized. Proliferative responses of CD4+ and CD8+ T cells against peptides were determined by the CFSE dilution assay. HLA class II binding assays were made to confirm the promiscuity of these peptides and evaluate their ability to bind the HLA molecules carried by each patient. Results: All tested peptides were recognized by at least one patient and proliferative responses of CD4+ and CD8+ T cells against at least one HIV-1 protease peptide were found in 78% and 75% patients, respectively. The third region (Protease 76-95) was the most frequently recognized. By comparing T-cell responses to HIV-1 endogenous protease sequences, we found that most patients failed to recognize identical peptides of those sequences, but recognized different variant peptides of the same region. Only seven patients responded to endogenous sequences. We found that several endogenous peptides that failed to be recognized showed no binding to the HLA alleles carried by that given patient, suggesting that mutations selected by immune pressure have led to escape of antigen presentation, as well as direct escape of the CD4+ T cell response. Alternatively, it could have been due to the presence of a different replicating virus in the plasma-since we only obtained proviral sequences. Conclusion: Wild-type and mutant HIV-1 protease epitopes recognized by CD4+ T cells were identified. We also found that most patients failed to recognize their endogenous protease sequences, while they recognized variant sequences. The recognition of non-endogenous sequences could hypothetically be a consequence of targeting a minor HIV-1 population; HERV protease, that contains regions of similarity with HIV-1 protease; or HIV-1 sequences present only in viremic partners. The failure to recognize endogenous sequences is most likely due to immune escape, either at the level of presentation or direct T cell recognition. This may have a pathophysiological consequence on evasion of T cell responses against protease and the fact that it has been considered traditionally a poorly antigenic HIV-1 protein.
Книги з теми "HIV-1 proteasi"
March, Darren. Designing new antiviral drugs for AIDS: HIV-1 protease and its inhibitors. Austin: R.G. Landes, 1996.
Знайти повний текст джерела1930-, Kostka Vladimír, and International Congress of Biochemistry (14th : 1988 : Prague, Czechoslovakia), eds. Proteases of retroviruses: Proceedings of the Colloquium C 52, 14th International Congress of Biochemistry, Prague, Czechoslovakia, July 10-15, 1988. Berlin: W. de Gruyter, 1989.
Знайти повний текст джерелаHarburn, James Jonathan. Novel steroidal inhibitors of HIV-1 protease. 1998.
Знайти повний текст джерелаKostka, Vladimir. Proteases of Retroviruses: Proceedings of the Colloquium C 52 14th International Congress of Biochemistry Prague, Czechoslovakia July 10-15, 1988. Walter De Gruyter Inc, 1989.
Знайти повний текст джерелаYoung, Benjamin. Classes of Antiretrovirals. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0019.
Повний текст джерелаLivingston, Schuyler, Benjamin Young, Martin Markowitz, Poonam Mathur, and Bruce L. Gilliam. HIV Virology. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0017.
Повний текст джерелаMajid, Adrian, and Bruce L. Gilliam. Future Antiretrovirals, Immune-Based Strategies, and Therapeutic Vaccines. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0023.
Повний текст джерелаMarkgren, Per-Olof. Analysis of the Interaction Between HIV-1 Protease and Inhibitors: Applications for Drug Discovery (Comprehensive Summaries of Uppsala Dissertations, 511). Uppsala Universitet, 1999.
Знайти повний текст джерелаHulten, Johan. Cyclic Sulfamides As HIV-1 Protease Inhibitors: Synthesis, X-Ray Structure Analysis and Structure-Activity Relationship (Comprehensive Summaries of Uppsala ... from the Faculty of Pharmacy, 213). Uppsala Universitet, 1999.
Знайти повний текст джерелаAndersson, Hans Ola. Structural-Aided Design of Antiviral Drugs: Application of the Method of HIV-1 Protease and Siv Reverse Transcriptase (Comprehensive Summaries of Uppsala ... the Faculty of Science and Technology, 477). Uppsala Universitet, 1999.
Знайти повний текст джерелаЧастини книг з теми "HIV-1 proteasi"
Weber, Irene T., Ying Zhang, and Jozsef Tözsér. "HIV-1 Protease and AIDS Therapy." In Viral Proteases and Antiviral Protease Inhibitor Therapy, 25–45. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2348-3_2.
Повний текст джерелаGeller, Maciej, Joanna Trylska, and Jan Antosiewicz. "HIV-1 Protease and its Inhibitors." In Theoretical and Computational Methods in Genome Research, 237–54. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-5903-0_18.
Повний текст джерелаDoyon, Louise, Robert Elston, and Pierre R. Bonneau. "Resistance to HIV-1 Protease Inhibitors." In Antimicrobial Drug Resistance, 477–92. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-180-2_34.
Повний текст джерелаSakurai, Mitsuya, Machiko Sugano, Susumu Higashida, Atsushi Kasuya, Shuichi Miyamoto, Hiroshi Handa, Tomoaki Komai, Ryuichi Yagi, Takashi Nishigaki, and Yuichiro Yabe. "Synthesis of HIV-1 protease inhibitors." In Peptide Chemistry 1992, 532–34. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1474-5_155.
Повний текст джерелаWilderspin, Andrew, Duncan Gaskin, Risto Lapatto, Tom Blundell, Andrew Hemmings, John Overington, Jim Pitts, et al. "Three-dimensional Structure and Evolution of HIV-1 Protease." In Retroviral Proteases, 79–91. London: Macmillan Education UK, 1990. http://dx.doi.org/10.1007/978-1-349-11907-3_10.
Повний текст джерелаDebouck, Christine, Ingrid C. Deckman, Stephan K. Grant, Robert J. Craig, and Michael L. Moore. "The HIV-1 Aspartyl Protease: Maturation and Substrate Specificity." In Retroviral Proteases, 9–17. London: Macmillan Education UK, 1990. http://dx.doi.org/10.1007/978-1-349-11907-3_3.
Повний текст джерелаPeng, Cheng, Karin Moelling, Nancy T. Chang, and Tse Wen Chang. "Functional Characterisation of HIV-1 gag-pol Fusion Protein." In Retroviral Proteases, 55–62. London: Macmillan Education UK, 1990. http://dx.doi.org/10.1007/978-1-349-11907-3_7.
Повний текст джерелаPotempa, Marc, Sook-Kyung Lee, Richard Wolfenden, and Ronald Swanstrom. "The Triple Threat of HIV-1 Protease Inhibitors." In The Future of HIV-1 Therapeutics, 203–41. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/82_2015_438.
Повний текст джерелаRoller, P. P., M. Nomizu, S. W. Snyder, S. Oroszlan, and J. B. McMahon. "Complementary peptides as inhibitors of HIV-1 protease." In Peptides, 709–10. Dordrecht: Springer Netherlands, 1992. http://dx.doi.org/10.1007/978-94-011-2264-1_283.
Повний текст джерелаVirgil, Scott C. "First-Generation HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS." In Aspartic Acid Proteases as Therapeutic Targets, 139–68. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2011. http://dx.doi.org/10.1002/9783527630943.ch6.
Повний текст джерелаТези доповідей конференцій з теми "HIV-1 proteasi"
Abdullah, Muhammad, Seher Ansar Khawaja, and Muhammad Farooq. "HIV-1 Protease Cleavages." In 2021 International Conference on Innovative Computing (ICIC). IEEE, 2021. http://dx.doi.org/10.1109/icic53490.2021.9692978.
Повний текст джерелаBarbosa, Karen Eduarda, and Jorge Alexandre Nogueira Santos. "ANÁLISE DO PAPEL DA ENZIMA HIV- 1 PROTEASE NO CICLO REPLICATIVO DO HIV." In I Congresso Nacional de Microbiologia Clínica On-Line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/1197.
Повний текст джерелаFarache Trajano, Luiza, Rebecca Moore, and Quentin Sattentau. "The Presence of Chemical Cross-Linking Stabilises HIV-1 Envelope Glycoprotein Trimer Antigens in a Model of Intramuscular Immunisation." In Building Bridges in Medical Science 2021. Cambridge Medicine Journal, 2021. http://dx.doi.org/10.7244/cmj.2021.03.001.4.
Повний текст джерелаYu, Xiaxia, Irene Weber, and Robert Harrison. "Sparse Representation for HIV-1 Protease Drug Resistance Prediction." In Proceedings of the 2013 SIAM International Conference on Data Mining. Philadelphia, PA: Society for Industrial and Applied Mathematics, 2013. http://dx.doi.org/10.1137/1.9781611972832.38.
Повний текст джерелаKumar, Sunil, Rajni Garg, Srinivas R. Alla, Xiaoyu Zhang, and Vivek K. Jalahalli. "3D-Shape analysis of the HIV-1 protease ligand binding site." In 2008 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB 2008). IEEE, 2008. http://dx.doi.org/10.1109/cibcb.2008.4675772.
Повний текст джерелаPeng, Xinzhan, Daniel R. Draney, and William M. Volcheck. "Quenched near-infrared fluorescent peptide substrate for HIV-1 protease assay." In Biomedical Optics 2006, edited by Samuel Achilefu, Darryl J. Bornhop, and Ramesh Raghavachari. SPIE, 2006. http://dx.doi.org/10.1117/12.669174.
Повний текст джерелаYou, Liwen, and Intelligent Systems Lab. "DETECTION OF CLEAVAGE SITES FOR HIV-1 PROTEASE IN NATIVE PROTEINS." In Proceedings of the Conference CSB 2006. PUBLISHED BY IMPERIAL COLLEGE PRESS AND DISTRIBUTED BY WORLD SCIENTIFIC PUBLISHING CO., 2006. http://dx.doi.org/10.1142/9781860947575_0031.
Повний текст джерелаOnuku, Raphael, Ngozi Nwodo, and Akachukwu Ibezim. "Repurposing Drugs to Find HIV-1 Protease Inhibitors: A Virtual Study." In MOL2NET'21, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 7th ed. Basel, Switzerland: MDPI, 2021. http://dx.doi.org/10.3390/mol2net-07-12067.
Повний текст джерелаKim, Gilhan, Yeonjoo Kim, and Hyeoncheol Kim. "Feature Selection using Multi-Layer Perceptron in HIV-1 Protease Cleavage Data." In 2008 International Conference on Biomedical Engineering And Informatics (BMEI). IEEE, 2008. http://dx.doi.org/10.1109/bmei.2008.169.
Повний текст джерелаNishimura, R. H. V., F. T. Toledo, and G. C. Clososki. "Preparation of New Magnesium Carbenoids Aiming Inhibitors of HIV-1 Protease Synthesis." In 15th Brazilian Meeting on Organic Synthesis. São Paulo: Editora Edgard Blücher, 2013. http://dx.doi.org/10.5151/chempro-15bmos-bmos2013_2013913171326.
Повний текст джерела